Results 81 to 90 of about 5,297,540 (313)

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +2 more sources

Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer

Zhongliu Fangzhi Yanjiu, 2022
The majority of diagnosed cases of gastric cancer are in the middle and late stages, while less than 10% of patients are diagnosed in the early stages in China.
CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong   +3 more
doaj   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

A current perspective on stereotactic body radiation therapy for pancreatic cancer. [PDF]

, 2016
Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients are unable to undergo resection, which remains the only potentially curative treatment option.
Czito, Brian G, Hong, Julian C, Palta, Manisha, Willett, Christopher G   +3 more
core   +2 more sources

Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

Cancer Immunology, Immunotherapy
Objective Hypopharyngeal squamous cell carcinoma (HSCC) is a highly malignant tumor type in the head and neck region. In recent years, neoadjuvant therapy has significantly improved the laryngeal preservation rate among patients.
Gaofei Yin, Nuan Li, Xiaohong Chen, Yang Zhang, Zhigang Huang, Wei Guo   +5 more
doaj   +1 more source

Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors

Translational Oncology
Neoadjuvant therapy is widely used for treating malignant tumors, but its efficacy varies among patients. Currently, tools or biomarkers for early and accurate evaluation of the efficacy of neoadjuvant therapy are lacking.
Jiayi Wang, Jiahui Dai, Yangxi Cheng, Xirui Wang, Rui Deng, Huiyong Zhu   +5 more
doaj   +1 more source

Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy

JAMA Oncology, 2019
Importance The watch-and-wait (WW) strategy aims to spare patients with rectal cancer unnecessary resection. Objective To analyze the outcomes of WW among patients with rectal cancer who had a clinical complete response to neoadjuvant therapy.
J. Smith, Paul Strombom, O. Chow, Campbell S. Roxburgh, Campbell S. Roxburgh, P. Lynn, A. Eaton, M. Widmar, K. Ganesh, R. Yaeger, A. Cercek, M. Weiser, G. Nash, J. Guillem, Larissa K.F. Temple, Sreedevi Chalasani, J. Fuqua, I. Petkovska, A. Wu, M. Reyngold, E. Vakiani, J. Shia, N. Segal, James D. Smith, C. Crane, M. Gollub, M. Gonen, L. Saltz, J. García-Aguilar, P. Paty   +29 more
semanticscholar   +1 more source

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer

JAMA Network Open, 2020
Key Points Question Is total neoadjuvant therapy (TNT) associated with improved outcomes when compared with standard concurrent chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A) for locally advanced rectal cancer?
A. Kasi, Saqib Abbasi, S. Handa, R. Al-Rajabi, A. Saeed, J. Baranda, Weijing Sun   +6 more
semanticscholar   +1 more source

Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer

Molecular Oncology, EarlyView.
COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann, Eduardo García‐Galea, Alice O'Farrell, Zak Kinsella, Maxime Meylan, Florent Petitprez, Ingrid Arijs, Tom Venken, Hari Ps, Adrian Lärkeryd, Ian Miller, Janick Selves, Nadja Meindl‐Beinker, Fiorella Ruiz‐Pace, Elena Élez, Raquel Comas‐Navarro, Frank Lincoln, Dirk Fey, Gift Nyamundanda, Aoife Nolan, Joern Lewin, Raquel Perez‐Lopez, Jonathan Briody, Kathleen Bennett, Walter Kolch, David Matallanas, Alexander Kel, Enrique Arenas, Joaquín Arribas, Bart Ghesquière, Josep Tabernero, Julie Meilleroux, Deborah McNamara, Ray McDermott, Marvin Lim, Mary O'Reilly, Brian Bird, Lisa Stack, Lucia Moloney, Patrick Morris, Keith Egan, Maciej Milewski, Lars Scheuer, Joachim Behringer, Georg Bolz, Ramon Salazar, Cristina Santos, Andrea Ruiz, Orla Casey, Verena Murphy, Matthias Ebert, Livio Trusolino, Diether Lambrechts, Anguraj Sadanandam, Catherine Sautès‐Fridman, Jochen Prehn, Paolo Nuciforo, Jacques Fieschi, Florence Monville, Darran O'Connor, Wolf Fridman, Annette Byrne   +61 more
wiley   +1 more source

Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer [PDF]

, 2017
This study aims to evaluate the feasibility of a magnetic resonance (MR) automatic method for quantitative assessment of the percentage of fibrosis developed within locally advanced rectal cancers (LARC) after neoadjuvant radiochemotherapy (RCT). A total
Bellini, D, Caruso, D, Caterino, Martina, Ciolina, M, De Santis, D, Laghi, A., Marzi, S, Musio, Daniela, Picchia, S, Rengo, M, Tombolini, V   +10 more
core   +1 more source